日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura

ADAMTS13 生物标志物在免疫性血栓性血小板减少性紫癜管理中的应用

Sui, Jingrui; Zheng, Liang; Zheng, X Long

Plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura.

血浆中 S100A8/A9、组蛋白/DNA 复合物和游离 DNA 的水平可预测免疫性血栓性血小板减少性紫癜的不良后果

Sui Jingrui, Lu Ruinan, Halkidis Konstantine, Kocher Nicole K, Cao Wenjing, Marques Marisa B, Zheng X Long

Elevated Plasma Fibrinogen Is Associated With Excessive Inflammation and Disease Severity in COVID-19 Patients

新冠肺炎患者血浆纤维蛋白原水平升高与过度炎症和疾病严重程度相关

Sui, Jingrui; Noubouossie, Denis F; Gandotra, Sheetal; Cao, Liyun

Cerebral Infarction in Immune Thrombotic Thrombocytopenic Purpura Is Associated with Old Age, Hypertension, Smoking, and Anti-ADAMTS13 Ig, But Not with Mortality

免疫性血栓性血小板减少性紫癜引起的脑梗死与高龄、高血压、吸烟和抗ADAMTS13 Ig相关,但与死亡率无关。

Memon, Raima; Sui, Jingrui; Lin, Chen; Zheng, X Long

Acute Respiratory Distress Syndrome in a Patient With Acute Promyelocytic Leukemia: Overlapping Between Differentiation Syndrome and COVID-19

急性早幼粒细胞白血病患者并发急性呼吸窘迫综合征:分化综合征与新冠肺炎的重叠

Sui, Jingrui; Kelmenson, Daniel; Hu, Shimin; Cao, Liyun

Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura

血浆中 Syndecan-1 和可溶性血栓调节蛋白水平升高可预测血栓性血小板减少性紫癜的不良预后

Lu, Ruinan; Sui, Jingrui; Zheng, X Long

NPM1A in Plasma is a Potential Prognostic Biomarker in Acute Myeloid Leukemia

血浆中的NPM1A是急性髓系白血病的潜在预后生物标志物

Sun, Chengming; Gao, Yujie; Yang, Liping; Shao, Huiyuan; Li, Jie; Gao, Xuejun; Ma, Li; Lin, Mingming; Sui, Jingrui